Markers with different fold-change expression between asymptomatic vs progressing high-risk SMM patients. Fold-change expression of CD16 in CD56^bright NK cells and of IL-2 and CD195 in CD4 T lymphocytes, from baseline to cycle 9 of induction therapy with LenDex. High-risk SMM patients were grouped into those remaining asymptomatic (n = 19) vs those progressing to symptomatic MM (n = 12). Boxes represent 25th and 75th percentile values; the line in the middle corresponds to the median value; vertical lines correspond to both the 10th and 90th percentiles.